Clinical Progress Update From PRO-101, a Hybrid Phase One Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Prosetin in Participants With ALS

prosetin - ProJenX

Erin Fleming1; Kristiana Salmon1; April Ruby1; Hilde Williams1; Ingela Danielsson-Sanden1

Mar 6, 2026